Your Article Summary
See Latest ArticlesReversal of refractory septic shock with drotrecogin alpha (activated)
Intensive Care Medicine, 07/02/09
Vieillard-Baron A et al. - The objective of this study was to investigate whether early administration of drotrecogin alpha (activated) (DrotAA) to this selected subgroup of septic patients at extremely high risk of death would significantly improve prognosis. DrotAA therapy was associated with unexpectedly high 28-day survival in patients with "refractory" septic shock.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA
Expert Review of Cardiovascular Therapy , 11/16/09